LD-2 disclosure · 1st Quarter - Report
MT PHARMA AMERICA, INC.
Client
- Name
- MT PHARMA AMERICA, INC.
- Description
- Pharmaceutical Company
- Location
- New Jersey · United States of America
Registrant
- Description
- Lobbying Law Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesMedicare/Medicaid
Matters affecting access to and pricing of pharmaceuticals. S 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and HR 3, Lower Drug Costs Now Act of 2019.
LobbyistsGEORGE OLSEN · KARINA LYNCH · mr DAVID A STARR · CHERYL LYNN JAEGER
Covered position (KARINA LYNCH): Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs
Covered position (CHERYL LYNN JAEGER): Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs, including S. 61 and H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 97 and H.R. 447, Affordable and Safe Prescription Drug Importation Act; Implementation of the Right to Try Act of 2017. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019; S.3548/H.R. 748, Coronavirus Aid, Relief, and Economic Security Act; H.R. 6201, Families First Coronavirus Response Act; and H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020.
LobbyistsGEORGE OLSEN · mr DAVID A STARR · CHERYL LYNN JAEGER